This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPsyBio Therapeutics（PSYB.H）株式概要PsyBio Therapeutics Corp.はバイオテクノロジー企業で、米国において精神疾患などの治療のためにサイケデリックな影響を受けた規制医薬品の研究、開発、商品化に従事している。 詳細PSYB.H ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析意味のある時価総額がありません ( CA$1M )収益が 100 万ドル未満 ( $0 )マイナスの株主資本 株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るPSYB.H Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW481,017 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA481,017 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.01該当なし内在価値ディスカウントEst. Revenue$PastFuture-8m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesPsyBio Therapeutics Corp. 競合他社Biocure TechnologySymbol: CNSX:CURE.XMarket cap: CA$1.1mEntheon BiomedicalSymbol: CNSX:ENBI.XMarket cap: CA$831.5kVaxil BioSymbol: TSXV:VXLMarket cap: CA$697.2kNAVCO PharmaceuticalsSymbol: TSXV:NAVMarket cap: CA$285.3k価格と性能株価の高値、安値、推移の概要PsyBio Therapeutics過去の株価現在の株価CA$0.0152週高値CA$0.02552週安値CA$0.005ベータ0.631ヶ月の変化n/a3ヶ月変化n/a1年変化-60.00%3年間の変化-97.22%5年間の変化n/aIPOからの変化-98.36%最新ニュースお知らせ • Mar 26PsyBio Therapeutics Listing Transfer from Tier 2 to NEXIn accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice.お知らせ • Jan 11PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of DirectorsPsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town.お知らせ • Dec 10PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMTPsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology.お知らせ • Dec 07PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioPsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field.お知らせ • Dec 02PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in fundingPsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Mar 26PsyBio Therapeutics Listing Transfer from Tier 2 to NEXIn accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice.お知らせ • Jan 11PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of DirectorsPsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town.お知らせ • Dec 10PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMTPsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology.お知らせ • Dec 07PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioPsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field.お知らせ • Dec 02PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in fundingPsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 12+ 1 more updatePsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical TrialPsyBio Therapeutics Corp. announces that it has reached an initial agreement with experienced clinical researchers to conduct a clinical trial utilizing PsyBio's proprietary biosynthetic psilocybin product upon obtaining all necessary approvals and licenses. The agreement between PsyBio and the clinical trial research team represents the first step towards conducting human clinical trials utilizing biosynthetic psilocybin. Additional details will be released as approvals are obtained, a definitive agreement is entered into and further specifics are available. This announcement demonstrates PsyBio's commitment to scientific advancements.お知らせ • Sep 20+ 1 more updateThe United States Patent and Trademark Office Accepts Patent Application of Psybio Therapeutics Latest U.S. Pct (Non-Provisional)PsyBio Therapeutics Corp. is announcing the formal acceptance by the United States Patent and Trademark Office of its latest U.S. PCT (Non-Provisional) Patent Application. The accepted patent application was submitted with information comprising advancements concerning production methodology, host strains and processes of production that support PsyBio's novel production methodology. These filings demonstrate the Company's commitment to value creation while promoting scientific and methodologic advancements in the field.お知らせ • Aug 09PsyBio Therapeutics Corp. Announces Expansion of Patent Portfolio with Additional Global Patent ApplicationsPsyBio Therapeutics Corp. announced the filing of additional international patent applications in Europe, Africa, and Asia. This brings PsyBio's total number of patent application submissions to twenty, making it one of the most robust portfolios in the sector. The patent applications submitted comprise advancements concerning production methodology, host strains and processes of production that support and allow PsyBio's novel production methodology to be globally protected. These filings demonstrate the Company's commitment to value creation, while also promoting scientific and methodologic advancements in the field.お知らせ • Jun 04PsyBio Therapeutics Corp. Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive CompoundsPsyBio Therapeutics Corp. has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufacturing Practice ("GMP") production. PsyBio's manufacturing process utilizes bioreactor manufacturing technology to facilitate expansion of PsyBio's portfolio of compounds. This process methodology is another necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for its therapeutic candidate portfolio Investigational New Drug ("IND") applications with the United States Food and Drug Administration ("FDA"). PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates at commercial scale. Commercial purification process development furthers the ability to manufacture compounds with predictable and reproducible purity.お知らせ • May 31Psybio Therapeutics Corp. Provides Corporate Update on Intellectual Property and Clinical Development MilestonesPsyBio Therapeutics Corp. provided shareholders with a corporate update. Intellectual Property and Clinical Development Milestones e Company recently announced that it achieved a commercially scalable purification method for one of its second-generation compounds. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section for an Investigational New Drug application with the United States Food and Drug Administration. The Company recently announced that it expanded its preclinical pipeline activities by initiating blood-brain barrier permeability testing. Favorable results from this type of testing are anticipated to expediate compound selection and progress toward the filing of an IND application with the FDA. The Company recently announced that it submitted an application to convert existing provisional patents to full patents. This submission covers major markets including North America, Europe, Asia-Pacific, and Africa as well as other important countries. The continued collaboration with Miami University is anticipated to expedite progress toward the filing of an IND application with the FDA. The Company recently announced that it is initiating the process of recruiting, evaluating, and selecting highly qualified investigators for upcoming clinical trials. The Company recently announced that it is in the process of drafting its second pre-IND application in anticipation of seeking IND approval from the FDA for clinical trials.お知らせ • May 18PsyBio Therapeutics Corp. Develops Commercial Purification Process for Second Generation Psycho-Targeted CompoundPsyBio Therapeutics Corp. reported that it has achieved a commercially scalable purification method for one of its second generation compounds. This manufacturing process achievement is expected to enable the commercial scale purification of bioreactor produced products utilizing manufacturing methodology to further expand PsyBio's portfolio of compounds that can be more readily and rapidly developed than competitive methods. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for this second-generation candidates Investigational New Drug application with the US Food and Drug Administration. PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapidgeneration of tryptamines and related compounds through a biosynthetic process using genetically modifiedbacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates atcommercial scale. Commercial purification process development furthers the ability to manufacture compoundswith predictable and reproducible purity.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Bob Oliver was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 14PsyBio Therapeutics Corp. Initiates Clinical Trial Site Selection ProcessPsyBio Therapeutics Corp. announced that it is initiating the process of recruiting, evaluating and selecting highly qualified investigators for upcoming clinical trials. PsyBio is currently in the process of drafting its second pre-IND application in anticipation of seeking investigational new drug ("IND") approval from the United States Food and Drug Administration for upcoming clinical trials. Once submitted and approved by the appropriate regulatory authorities, including the FDA, clinical investigators will be selected and trained to conduct clinical investigations, which will help facilitate rapid trial initiation and completion.お知らせ • Apr 13PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022.分析記事 • Jan 05Will PsyBio Therapeutics (CVE:PSYB) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Sep 24PsyBio Therapeutics Announces Pre-IND Application Request Has Been Submitted to the United States Food and Drug AdministrationPsyBio Therapeutics Corp. reported it has submitted its first pre-Investigational New Drug ("IND") application meeting request to the United States Food and Drug Administration ("FDA") as part of the regulatory submission process. The FDA'sPre-Investigational New Drug Application (IND) Consultation Program fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission.[1] PsyBio is dedicated to working towards obtaining all necessary regulatory approvals for its therapeutics under development and intends to submit its most promising potential therapeutic candidates to the appropriate regulatory body as part of the approval process. The submission of this pre-IND meeting request for collaborative discussions with the FDA has been submitted in anticipation of filing the first of several clinical IND packages.分析記事 • Sep 16Companies Like PsyBio Therapeutics (CVE:PSYB) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jul 15PsyBio Therapeutics Corp. Files A New Provisional Patent Application with the United States Patent and Trademark Office Entitled Psilocybin and Norbaeocystin Compositions and Methods of TreatmentPsyBio Therapeutics Corp. filed a new provisional patent application with the United States Patent and Trademark Office entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment. The Patent Application contains 67 new inventive claims and further demonstrates the Company's vision to build a strong intellectual property portfolio protecting numerous novel psychedelic drug candidatesbeing developed for clinical trial evaluations. PsyBio's intellectual property portfolio now includes five pending provisionals and one pending non-provisional patent application.お知らせ • Jun 23Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic CompoundsPsyBio Therapeutics Corp. has initiated its first, European pilot scale batch manufacturing of its psychedelic portfolio of compounds with the proprietary biosynthetic formulation of psilocybin in collaboration with Biose Industrie ("Biose"), an expert in commercializing pharmaceutical products based on live bacterial production, to prepare products and substances for ongoing regulatory evaluation.分析記事 • Jun 02Companies Like PsyBio Therapeutics (CVE:PSYB) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Executive Departure • Apr 30Director has left the companyOn the 21st of April, Gerald Goldberg's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Gerald's name. Gerald is the only executive to leave the company over the last 12 months.お知らせ • Mar 03PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Albany Molecular Research IncPsyBio Therapeutics Corp. has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. The Company has completed Phase I of this process, including technology transfer activities, preparation of strain banks, and the adoption of analytical methods and looks forward to communicating additional progress.株主還元PSYB.HCA BiotechsCA 市場7D0%1.0%-0.4%1Y-60.0%27.1%30.2%株主還元を見る業界別リターン: PSYB.H過去 1 年間で27.1 % の収益を上げたCanadian Biotechs業界を下回りました。リターン対市場: PSYB.Hは、過去 1 年間で30.2 % のリターンを上げたCanadian市場を下回りました。価格変動Is PSYB.H's price volatile compared to industry and market?PSYB.H volatilityPSYB.H Average Weekly Movementn/aBiotechs Industry Average Movement10.5%Market Average Movement9.4%10% most volatile stocks in CA Market16.3%10% least volatile stocks in CA Market3.7%安定した株価: PSYB.H 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のPSYB.Hのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2009n/aEvan Levinewww.psybiolife.comPsyBio Therapeutics Corp.はバイオテクノロジー企業であり、米国で精神疾患やその他の疾患の治療薬としてサイケデリックに着想を得た規制医薬品の研究、開発、商品化に取り組んでいる。PsyBio Therapeutics Corp.の前身はLeo Acquisitions Corp.で、2021年1月にPsyBio Therapeutics Corp.に社名変更した。本社はコロラド州デンバー。もっと見るPsyBio Therapeutics Corp. 基礎のまとめPsyBio Therapeutics の収益と売上を時価総額と比較するとどうか。PSYB.H 基礎統計学時価総額CA$1.33m収益（TTM）-CA$2.63m売上高(TTM)n/a0.0xP/Sレシオ-0.5xPER（株価収益率PSYB.H は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PSYB.H 損益計算書（TTM）収益US$0売上原価US$50.00k売上総利益-US$50.00kその他の費用US$1.85m収益-US$1.90m直近の収益報告Jun 30, 2023次回決算日該当なし一株当たり利益（EPS）-0.014グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%PSYB.H の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/30 05:59終値2024/07/26 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PsyBio Therapeutics Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Robert LeBoyerNOBLE Capital Markets, Inc.
お知らせ • Mar 26PsyBio Therapeutics Listing Transfer from Tier 2 to NEXIn accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice.
お知らせ • Jan 11PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of DirectorsPsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town.
お知らせ • Dec 10PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMTPsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology.
お知らせ • Dec 07PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioPsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field.
お知らせ • Dec 02PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in fundingPsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 26PsyBio Therapeutics Listing Transfer from Tier 2 to NEXIn accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice.
お知らせ • Jan 11PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of DirectorsPsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town.
お知らせ • Dec 10PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMTPsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology.
お知らせ • Dec 07PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioPsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field.
お知らせ • Dec 02PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in fundingPsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 12+ 1 more updatePsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical TrialPsyBio Therapeutics Corp. announces that it has reached an initial agreement with experienced clinical researchers to conduct a clinical trial utilizing PsyBio's proprietary biosynthetic psilocybin product upon obtaining all necessary approvals and licenses. The agreement between PsyBio and the clinical trial research team represents the first step towards conducting human clinical trials utilizing biosynthetic psilocybin. Additional details will be released as approvals are obtained, a definitive agreement is entered into and further specifics are available. This announcement demonstrates PsyBio's commitment to scientific advancements.
お知らせ • Sep 20+ 1 more updateThe United States Patent and Trademark Office Accepts Patent Application of Psybio Therapeutics Latest U.S. Pct (Non-Provisional)PsyBio Therapeutics Corp. is announcing the formal acceptance by the United States Patent and Trademark Office of its latest U.S. PCT (Non-Provisional) Patent Application. The accepted patent application was submitted with information comprising advancements concerning production methodology, host strains and processes of production that support PsyBio's novel production methodology. These filings demonstrate the Company's commitment to value creation while promoting scientific and methodologic advancements in the field.
お知らせ • Aug 09PsyBio Therapeutics Corp. Announces Expansion of Patent Portfolio with Additional Global Patent ApplicationsPsyBio Therapeutics Corp. announced the filing of additional international patent applications in Europe, Africa, and Asia. This brings PsyBio's total number of patent application submissions to twenty, making it one of the most robust portfolios in the sector. The patent applications submitted comprise advancements concerning production methodology, host strains and processes of production that support and allow PsyBio's novel production methodology to be globally protected. These filings demonstrate the Company's commitment to value creation, while also promoting scientific and methodologic advancements in the field.
お知らせ • Jun 04PsyBio Therapeutics Corp. Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive CompoundsPsyBio Therapeutics Corp. has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufacturing Practice ("GMP") production. PsyBio's manufacturing process utilizes bioreactor manufacturing technology to facilitate expansion of PsyBio's portfolio of compounds. This process methodology is another necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for its therapeutic candidate portfolio Investigational New Drug ("IND") applications with the United States Food and Drug Administration ("FDA"). PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates at commercial scale. Commercial purification process development furthers the ability to manufacture compounds with predictable and reproducible purity.
お知らせ • May 31Psybio Therapeutics Corp. Provides Corporate Update on Intellectual Property and Clinical Development MilestonesPsyBio Therapeutics Corp. provided shareholders with a corporate update. Intellectual Property and Clinical Development Milestones e Company recently announced that it achieved a commercially scalable purification method for one of its second-generation compounds. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section for an Investigational New Drug application with the United States Food and Drug Administration. The Company recently announced that it expanded its preclinical pipeline activities by initiating blood-brain barrier permeability testing. Favorable results from this type of testing are anticipated to expediate compound selection and progress toward the filing of an IND application with the FDA. The Company recently announced that it submitted an application to convert existing provisional patents to full patents. This submission covers major markets including North America, Europe, Asia-Pacific, and Africa as well as other important countries. The continued collaboration with Miami University is anticipated to expedite progress toward the filing of an IND application with the FDA. The Company recently announced that it is initiating the process of recruiting, evaluating, and selecting highly qualified investigators for upcoming clinical trials. The Company recently announced that it is in the process of drafting its second pre-IND application in anticipation of seeking IND approval from the FDA for clinical trials.
お知らせ • May 18PsyBio Therapeutics Corp. Develops Commercial Purification Process for Second Generation Psycho-Targeted CompoundPsyBio Therapeutics Corp. reported that it has achieved a commercially scalable purification method for one of its second generation compounds. This manufacturing process achievement is expected to enable the commercial scale purification of bioreactor produced products utilizing manufacturing methodology to further expand PsyBio's portfolio of compounds that can be more readily and rapidly developed than competitive methods. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for this second-generation candidates Investigational New Drug application with the US Food and Drug Administration. PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapidgeneration of tryptamines and related compounds through a biosynthetic process using genetically modifiedbacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates atcommercial scale. Commercial purification process development furthers the ability to manufacture compoundswith predictable and reproducible purity.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Bob Oliver was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 14PsyBio Therapeutics Corp. Initiates Clinical Trial Site Selection ProcessPsyBio Therapeutics Corp. announced that it is initiating the process of recruiting, evaluating and selecting highly qualified investigators for upcoming clinical trials. PsyBio is currently in the process of drafting its second pre-IND application in anticipation of seeking investigational new drug ("IND") approval from the United States Food and Drug Administration for upcoming clinical trials. Once submitted and approved by the appropriate regulatory authorities, including the FDA, clinical investigators will be selected and trained to conduct clinical investigations, which will help facilitate rapid trial initiation and completion.
お知らせ • Apr 13PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022.
分析記事 • Jan 05Will PsyBio Therapeutics (CVE:PSYB) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Sep 24PsyBio Therapeutics Announces Pre-IND Application Request Has Been Submitted to the United States Food and Drug AdministrationPsyBio Therapeutics Corp. reported it has submitted its first pre-Investigational New Drug ("IND") application meeting request to the United States Food and Drug Administration ("FDA") as part of the regulatory submission process. The FDA'sPre-Investigational New Drug Application (IND) Consultation Program fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission.[1] PsyBio is dedicated to working towards obtaining all necessary regulatory approvals for its therapeutics under development and intends to submit its most promising potential therapeutic candidates to the appropriate regulatory body as part of the approval process. The submission of this pre-IND meeting request for collaborative discussions with the FDA has been submitted in anticipation of filing the first of several clinical IND packages.
分析記事 • Sep 16Companies Like PsyBio Therapeutics (CVE:PSYB) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jul 15PsyBio Therapeutics Corp. Files A New Provisional Patent Application with the United States Patent and Trademark Office Entitled Psilocybin and Norbaeocystin Compositions and Methods of TreatmentPsyBio Therapeutics Corp. filed a new provisional patent application with the United States Patent and Trademark Office entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment. The Patent Application contains 67 new inventive claims and further demonstrates the Company's vision to build a strong intellectual property portfolio protecting numerous novel psychedelic drug candidatesbeing developed for clinical trial evaluations. PsyBio's intellectual property portfolio now includes five pending provisionals and one pending non-provisional patent application.
お知らせ • Jun 23Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic CompoundsPsyBio Therapeutics Corp. has initiated its first, European pilot scale batch manufacturing of its psychedelic portfolio of compounds with the proprietary biosynthetic formulation of psilocybin in collaboration with Biose Industrie ("Biose"), an expert in commercializing pharmaceutical products based on live bacterial production, to prepare products and substances for ongoing regulatory evaluation.
分析記事 • Jun 02Companies Like PsyBio Therapeutics (CVE:PSYB) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Executive Departure • Apr 30Director has left the companyOn the 21st of April, Gerald Goldberg's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Gerald's name. Gerald is the only executive to leave the company over the last 12 months.
お知らせ • Mar 03PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Albany Molecular Research IncPsyBio Therapeutics Corp. has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. The Company has completed Phase I of this process, including technology transfer activities, preparation of strain banks, and the adoption of analytical methods and looks forward to communicating additional progress.
